FewerJobs.
All jobs

Vice President, Patents

Revolution Medicines - Redwood City, California, United States

Posted Apr 11, 2026

Benefits

Parental leave
Not verified
Non-birth-parent leave
Not verified
Family-building benefits
  • Fertility benefits: Not verified
  • Adoption assistance: Not verified
  • Surrogacy assistance: Not verified
Mental health support
Not verified
Relocation assistance
Not verified
Childcare support
Not verified
Learning budget
Not verified
Verification
Not verified checked Jun 7, 2026
Salary
$354K-$408K From the posting source checked Jun 20, 2026
401(k) match
Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)
$117,235 U.S. median for this role
Projected growth (BLS Employment Projections)
+2.6% - Average

225% above the BLS role benchmark for legal aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 23-1011 - Legal aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function
Legal From the posting source checked Jun 20, 2026
Seniority
Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type
Not verified
Weekend work
Not verified

Company

Equity
Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter
Not verified
Assessment
Not verified
Deadline
Not stated

Where they hire

State eligibility is not yet verified.

About this role

Vice President, Patents Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished and highly strategic patent attorney to lead intellectual property strategy for our patent portfolio. This role is designed for a senior expert who can operate at the intersection of sophisticated patent prosecution and patent disputes within one of the most competitive areas in oncology. Reporting to the VP of IP, this individual will serve as our patent portfolio lead, with responsibility for developing and integrating global prosecution and challenge (both offensive and defensive) strategies. The role will function as a key strategic partner to the VP and a trusted advisor to senior leadership, with a primary focus on strengthening the durability and value of company assets worldwide, anticipating competitive threats, and identifying and mitigating vulnerabilities. This position may include management responsibility for members of the IP team, such as those handling patent prosecution. However, people management is not required

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.

Apply at revmed.com

Apply link not verified; last-live date unavailable.

What verified means

Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.

Related jobs